SCHEMBL4795185

SCHEMBL4795185

NC(Cc1ccc(-c2ccccc2)cc1)C(=O)N1CCN(c2ccc(F)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.60
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
SLC6A7 Q99884 1/20 0.59
AKT1 P31749 5/20 0.59
AKT2 P31751 3/20 0.59
AKT3 Q9Y243 3/20 0.59
POLB P06746 2/20 0.57
KDM4E B2RXH2 1/20 0.53
ROCK2 O75116 1/20 0.53
CYP3A4 P08684 1/20 0.53
GFER P55789 1/20 0.52
TP53 P04637 1/20 0.51
AKT1S1 Q96B36 1/20 0.50
GRM5 P41594 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
TSHR P16473 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4772342 0.93 POLB (0.62) AKT1AKT2AKT3POLBKDM4E
Hydrochloric Acid SCHEMBL6980746 0.92 POLB (0.61) AKT1AKT2AKT3POLBKDM4E
SCHEMBL4775798 0.86 MEN1 (0.64) MEN1KMT2AAKT1AKT2AKT3
SCHEMBL4776488 0.86 MAPT (0.58) DPP4MEN1KMT2AAKT1AKT2
SCHEMBL4776886 0.85 AKT1 (0.56) DPP4AKT1AKT2AKT3POLB
SCHEMBL4770054 0.83 AKT1 (0.57) DPP4AKT1AKT2AKT3POLB
SCHEMBL7506193 0.81 DPP4 (0.70) DPP4AKT1AKT2AKT3TSHR
SCHEMBL10305133 0.81 DPP4 (0.70) DPP4AKT1AKT2AKT3TSHR
SCHEMBL4772716 0.81 AKT1 (0.57) DPP4AKT1AKT2AKT3CYP3A4
SCHEMBL4773309 0.81 AKT1 (0.57) DPP4MEN1KMT2AAKT1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP claimed
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US claimed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO claimed
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof HNMT, HDAC5, HDAC4 DPP4 616/4885MEN1 1807/4885KMT2A 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.